For the chronic treatment of adults with pulmonary arterial hypertension (PAH, WHO Group I and WHO Functional Class [FC] II-III)1

For the chronic treatment of adults with pulmonary arterial hypertension (PAH, WHO Group I and WHO Functional Class [FC] II-III)1

OPSYNVI® (macitentan/tadalafil) demonstrated greater reduction in PVR after 16 weeks vs tadalafil or macitentan monotherapy. Most common adverse reactions (≥10%) were edema/fluid retention, anemia, and headache/migraine.1

OPSYNVI® (macitentan/tadalafil) demonstrated greater reduction in PVR after 16 weeks vs tadalafil or macitentan monotherapy. Most common adverse reactions (≥10%) were edema/fluid retention, anemia, and headache/ migraine.1

FDA=US Food and Drug Administration; PAH=pulmonary arterial hypertension; PVR=pulmonary vascular resistance; WHO=World Health Organization.

References: 1. OPSYNVI® (macitentan/tadalafil) full Prescribing Information. Actelion Pharmaceuticals US, Inc 2. Grünig E, Jansa P, Fan F, et al. Randomized trial of macitentan/tadalafil single-tablet combination therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2024;83(4):473-484. 3. Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2022;43(38):3618-3731.